Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; provision of chemical macromolecule contract development manufacture organization (CDMO) solutions for polypeptides, oligonucleotides, glycans, toxins-linkers and other macromolecules; biosynthesis solutions; biologics CDMO solutions for monoclonal antibodies and antibody-drug conjugates; and contract research organization solutions and messenger RNA solutions. In addition, the company is involved in development and drug product manufacturing; provision of pharmaceutical analysis and testing services; medical research and development; manufacturing, sale, and development of medicine raw materials and relevant products; sale of drug products; pharmaceuticals and chemical manufacturing; wholesaling and retailing of drugs; sale, import and export trade; information technology; technology development; and research and experimental development activities. The company was founded in 1998 and is headquartered in Tianjin, China.
Metrics to compare | 6821 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6821PeersSector | |
---|---|---|---|---|
P/E Ratio | 36.5x | 23.8x | −0.5x | |
PEG Ratio | −0.51 | 0.14 | 0.00 | |
Price/Book | 1.7x | 2.1x | 2.6x | |
Price / LTM Sales | 5.0x | 2.9x | 3.0x | |
Upside (Analyst Target) | 4.5% | 21.2% | 53.8% | |
Fair Value Upside | Unlock | 9.1% | 9.2% | Unlock |